A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia
Androgenetic Alopecia
About this trial
This is an interventional treatment trial for Androgenetic Alopecia focused on measuring Androgenetic Alopecia, CKD-498
Eligibility Criteria
Key Inclusion Criteria: Female of age 19-54 years Clinical Diagnosis of Androgenetic Alopecia Written informed consent Key Exclusion Criteria: Other types of Alopecia or other diseases that can cause hair loss Clinically significant scalp disease such as seborrheic dermatitis or psoriasis Clinically significant hepatic disease, thyroid disease, or mental illness, as determined by the Investigator Women who are pregnant or breastfeeding Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the last dose of study drug
Sites / Locations
- Seoul National University Bundang HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Placebo Comparator
Test Group1
Test Group2
Test Group3
Placebo Group